Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree?

Bruce R. Schackman, Paul A. Teixeira, Gil Weitzman, Alvin I. Mushlin and Ira M. Jacobson
Additional contact information
Bruce R. Schackman: Department of Public Health, Weill Medical College of Cornell University, brs2006@med.cornell.edu
Paul A. Teixeira: Department of Public Health, Weill Medical College of Cornell University
Gil Weitzman: Department of Medicine, Division of Gastroenterology and Hepatology and the Center for the Study of Hepatitis C Weill Medical College of Cornell University, New York
Alvin I. Mushlin: Department of Public Health, Weill Medical College of Cornell University
Ira M. Jacobson: Department of Medicine, Division of Gastroenterology and Hepatology and the Center for the Study of Hepatitis C Weill Medical College of Cornell University, New York

Medical Decision Making, 2008, vol. 28, issue 2, 233-242

Abstract: Background . Chronic hepatitis C (HCV) treatment is initiated infrequently by patients in urban settings. These patients often decline HCV treatment due to concerns about treatment side effects and have communication problems with their physicians. Methods . The authors investigated differences between how patients and providers evaluate the quality-of-life tradeoffs associated with HCV treatment in computer-assisted interviews. They interviewed 92 treatment-naive HCV patients at gastroenterology, methadone maintenance, and HIV clinics at 3 hospitals in New York City and 23 physicians or nurses experienced in treating HCV at other hospitals in New York City. Subjects completed rating scale and standard gamble evaluations of current health and hypothetical descriptions of HCV symptoms and treatment side effects on a scale from 0 (death or worse than death) to 1 (best possible health). Results . Treatment side effects were rated worse by patients than providers using the rating scale (moderate side effects 0.42 v. 0.62; severe side effects 0.24 v. 0.40) and standard gamble (moderate side effects 0.61 v. 0.91; severe side effects 0.52 v. 0.75) (all P ≤ 0.01 ). A year of severe side effects was equivalent to 4.1 years of mild HCV symptoms avoided for patients if they returned to their current health after treatment compared with 2.0 years avoided if they achieved average population health. For patients with depression symptoms, HCV treatment with severe side effects had lower value unless it would also improve their current health. Conclusions . Patients have more concerns about treatment side effects than providers. Further research is warranted to develop HCV decision aids that elicit patient preferences and to evaluate how improved communication of the risks and benefits of HCV treatment and more effective treatment of depression may alter these preferences.

Keywords: patient preference; treatment acceptance; physician-patient relations; quality of life; hepatitis C. (search for similar items in EconPapers)
Date: 2008
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X07311753 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:28:y:2008:i:2:p:233-242

DOI: 10.1177/0272989X07311753

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().